Celgene to Pay $1 Billion for Biotech Collaboration With Juno by ANDREW POLLACK

By ANDREW POLLACK

As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use patients’ immune systems to attack tumors.

Published: June 30, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1U1N1Kg

from WordPress http://ift.tt/1GIP7Ey
via Hadi Aboukhater